Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Haematology

• Publication date

  2011-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1365-2141.2010.08507.xPMID 21352196
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

  2010cited by this paper
• Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

  2010cited by this paper
• Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.

  2010cited by this paper
• Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.

  2010cited by this paper
• Differential heat shock protein localization in chronic lymphocytic leukemia

  2010cited by this paper
• Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro

  2009cited by this paper
• The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

  2009cited by this paper
• Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

  2009cited by this paper
• Heat Shock Protein 90 as a Drug Target: Some Like It Hot

  2009influential reference
• Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

  2009cited by this paper
• The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression

  2009cited by this paper
• 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

  2008cited by this paper
• ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.

  2008cited by this paper
• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  2008influential reference
• Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib

  2008influential reference
• Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells

  2008cited by this paper
• Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

  2008cited by this paper
• Phase II Study of Dasatinib in Patients with Relapsed CLL

  2008cited by this paper
• Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial

  2008cited by this paper
• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008influential reference
• Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

  2008cited by this paper
• The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

  2008cited by this paper
• SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

  2008cited by this paper
• c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.

  2008cited by this paper
• Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia.

  2008cited by this paper
• c-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL.

  2007cited by this paper
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

  2007cited by this paper
• CD154 induces a switch in pro‐survival Bcl‐2 family members in chronic lymphocytic leukaemia

  2007influential reference
• Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia

  2007cited by this paper
• Separate cell culture conditions to promote proliferation or quiescent cell survival in chronic lymphocytic leukemia

  2007cited by this paper
• ITAM-mediated tonic signalling through pre-BCR and BCR complexes

  2006cited by this paper
• c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.

  2006cited by this paper
• Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression.

  2006cited by this paper
• In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

  2005cited by this paper
• ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.

  2005cited by this paper
• Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

  2005cited by this paper
• B cell antigen receptor signaling 101.

  2004influential reference
• CD40: A Growing Cytoplasmic Tale

  2004cited by this paper
• Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.

  2004cited by this paper
• Chronic lymphocytic leukemia: revelations from the B-cell receptor.

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells

  2004cited by this paper
• Chronic lymphocytic leukemia : revelations from the B-cell receptor

  2004cited by this paper
• Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.

  2003cited by this paper
• Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells

  2001cited by this paper
• Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1

  2000cited by this paper
• Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.

  2000cited by this paper
• Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

  2000cited by this paper
• Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

  1999cited by this paper
• Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells.

  1998cited by this paper
• bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.

  1993influential reference
• A new generation of Ca2+ indicators with greatly improved fluorescence properties.

  1985cited by this paper

• The role of SYK phosphorylation in LPS-induced immunoglobulin responses of B cells in large yellow croaker (Larimichthys crocea).

  2025cites this paper
• B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia

  2024cites this paper
• Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways

  2024cites this paper
• Emerging Therapies in CLL in the Era of Precision Medicine

  2023cites this paper
• Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt’s lymphoma

  2023cites this paper
• PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling

  2022cites this paper
• In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia

  2021cites this paper
• Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

  2020cites this paper
• A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations

  2020cites this paper
• Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

  2019cites this paper
• Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking.

  2019cites this paper
• TARGETING THE MALIGNANT B CELL MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2019cites this paper
• Bruton’s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes

  2019cites this paper
• Elevated IL‐17A and IL‐22 regulate expression of inducible CD38 and Zap‐70 in chronic lymphocytic leukemia

  2018cites this paper
• AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival

  2018cites this paper
• Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment

  2017cites this paper
• Pharmacogenomics of Primary Blood Cancer Cells

  2017cites this paper
• Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

  2017cites this paper
• 19 Heat Shock Proteins in Chronic Lymphocytic Leukaemia

  2017cites this paper
• Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.

  2017cites this paper
• Bioinformatic tools for analysis, mining and modelling large-scale gene expression and drug testing datasets: Bioinformatic tools for analyzing large-scale biomedical datasets

  2016cites this paper
• Phenotypic Approaches to Identify Inhibitors of B Cell Activation

  2015influential citation
• Investigation into the efficacy of the anti-CD20 monoclonal antibody ofatumumab in chronic lymphocytic leukaemia

  2015cites this paper
• MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

  2015cites this paper
• CME Information: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

  2015cites this paper
• B-cell receptor signaling in the pathogenesis of lymphoid malignancies.

  2015cites this paper
• The targeting of human and mouse B lymphocytes by dasatinib.

  2015cites this paper
• Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.

  2015cites this paper
• Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes

  2015cites this paper
• Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

  2014cites this paper
• B-cell expansion and lymphomagenesis induced by chronic CD40 signaling is strictly dependent on CD19.

  2014cites this paper
• Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.

  2014cites this paper
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

  2014cites this paper
• Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice

  2014cites this paper
• Does B Cell Receptor Signaling in Chronic Lymphocytic Leukaemia Cells Differ from That in Other B Cell Types?

  2014cites this paper
• Protein kinase C in cellular transformation: a valid target for therapy?

  2014cites this paper
• Lymphocytes from chronic lymphocytic leukaemia undergo ABL1-linked amoeboid motility and homotypic interaction as an early adaptive change to ex vivo culture

  2014cites this paper
• Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

  2014cites this paper
• Role of chemokines and their receptors in chronic lymphocytic leukemia

  2014cites this paper
• Targeting Susceptible Signaling Pathways in Chronic Lymphocytic Leukemia

  2014cites this paper
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

  2013cites this paper
• Interleukin 22 is increased and correlated with CD38 expression in patients with B-chronic lymphocytic leukemia.

  2013cites this paper
• Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells

  2013cites this paper
• Towards targeted therapy of chronic lymphocytic leukemia.

  2013cites this paper
• Cosimo, Emilio et al. (2014) Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells. Clinical Cancer

  2013cites this paper
• Use of in vitro primary culture models to investigate the activity of standard and novel therapies in haematological malignancies

  2013cites this paper
• CK2 as a Logical Target in Cancer Therapy: Potential for Combining CK2 Inhibitors with Various Classes of Cancer Therapeutic Agents

  2013cites this paper
• Biology of Chronic Lymphocytic Leukemia in Different

  2013cites this paper
• Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

  2013cites this paper
• Gads is a Regulator of Normal and Leukemic Hematopoiesis

  2013cites this paper
• This information is current as Receptor Signaling and Syk in the Initiation of B-Cell Antigen Nonredundant Roles of Src-Family Kinases and

  2013cites this paper
• Chronic lymphocytic leukaemia – the role of the microenvironment pathogenesis and therapy

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Nonredundant Roles of Src-Family Kinases and Syk in the Initiation of B-Cell Antigen Receptor Signaling

  2013cites this paper
• A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization.

  2013cites this paper
• Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

  2013influential citation
• Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

  2013cites this paper
• Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches

  2012cites this paper
• Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12

  2012cites this paper
• Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

  2012cites this paper
• Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

  2012cites this paper
• Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

  2012cites this paper
• Dasatinib Inhibits CXCR 4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL 12

  2012cites this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cites this paper
• Comparison of the Effects of Two Kinase Inhibitors, Sorafenib and Dasatinib, on Chronic Lymphocytic Leukemia Cells

  2012cites this paper
• Heat Shock Proteins in Chronic Lymphocytic Leukaemia

  2012cites this paper
• A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition.

  2012cites this paper
• Crosstalk between ROR 1 and the pre-B-Cell Receptor Promotes Survival of t ( 1 ; 19 ) Acute Lymphoblastic Leukemia

  2012cites this paper
• Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype

  2012cites this paper
• Identification of new cytogenetic subgroups in chronic lymphocytic leukemia by combining genomic , exomic and transcriptomic profiling techniques

  2012cites this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cites this paper
• Delineation of molecular events that occur in a PKCα-KR-mediated murine model of CLL

  2012cites this paper
• Signal transduction inhibitors in chronic lymphocytic leukemia

  2011cites this paper
• B-cell receptor signaling in chronic lymphocytic leukemia.

  2011cites this paper
• Parsimonious discovery of synergistic drug combinations.

  2011cites this paper
• Clinicoeconomics and Outcomes Research Dovepress

  year unknowncites this paper